ALR Technologies SG Ltd. (OTC: ALRTF)

ALR Technologies SG Ltd. is a data management company that provides a comprehensive approach to diabetes care. Its core offering is the FDA‑cleared and HIPAA‑compliant Diabetes Solution product, which collects data from blood glucose meters and continuous glucose monitors, incorporates a patent‑pending Predictive A1C algorithm, and includes an FDA‑cleared Insulin Dosing Adjustment program. The company also markets the GluCurve Pet CGM product for animal health, pairing CGM hardware with adapted software to deliver remote glucose monitoring for diabetic pets.

ALR Technologies SG Ltd. generates revenue primarily from the sale of its Diabetes Solution product and GluCurve Pet CGM product, including bundled offerings with glucose monitoring hardware and related supplies. The company also earns revenue through distribution agreements, such as the co‑branded products agreement with Covetrus for GluCurve Pet CGM in the United States, Brazil, the United Kingdom, the European Union and other territories. In 2023 the company recorded $25,536 in revenue, while it reported no revenue for the years ended December 31, 2024 and December 31, 2025.

The company operates through the following segments.

• Diabetes Solution: This segment provides an FDA‑cleared and HIPAA‑compliant diabetes management system that collects data from BGM and CGM devices, features a patent‑pending Predictive A1C algorithm to track treatment success between lab reports, and includes an FDA‑cleared Insulin Dosing Adjustment program that offers dosage recommendations based on ADA and AACE guidelines. It is designed for human health, targeting patients with diabetes and healthcare providers seeking remote monitoring and therapy advancement suggestions.

• GluCurve Pet CGM: This segment offers a continuous glucose monitoring system for diabetic felines and canines that pairs CGM hardware with an adapted version of the Diabetes Solution software, delivering automatic glucose readings to a cloud platform where they are converted into daily glucose curve graphs and data sets for veterinarian review. It provides insulin dose calculators, decision flowcharts and guideline‑based recommendations, aiming to replace manual in‑clinic glucose curves and reduce burden on clinic staff, pets and pet owners.

ALR Technologies SG Ltd. competes in the diabetes monitoring and management market against larger players such as Livongo, Glooko, WellDoc, Medtronic, iGlucose and Microsoft HealthVault for human health solutions, and against traditional blood glucose monitor systems like AlphaTRAK and off‑label human CGM use in the animal health sector. Its competitive advantages include FDA clearance, HIPAA compliance, a patent‑pending Predictive A1C feature, an FDA‑cleared Insulin Dosing Adjustment program, and an integrated software‑hardware approach that addresses data overload, clinical inertia and insulin under prescription. These differentiators aim to provide cost‑effective, comprehensive diabetes care that improves patient outcomes and reduces healthcare costs.

The company serves healthcare providers, medical clinics, hospitals and patients with diabetes for its Diabetes Solution product, and veterinary clinics, animal health distributors and pet owners for its GluCurve Pet CGM product. Specific customers and collaborators mentioned in the filing include Bionime in Singapore, Singapore General Hospital, Diabetes Singapore, and Covetrus, which holds distribution rights for GluCurve Pet CGM in the United States, Brazil, the United Kingdom, the European Union and other territories.